Clinical review required: PRF is an adjunct prepared from a patient’s blood. Its value depends on indication and protocol; it is not a universal substitute for diagnosis, surgery or structural grafting.

What is PRF therapy?

Platelet-rich fibrin is an autologous blood concentrate used as a clot, plug, membrane or injectable preparation in dental surgery. A small volume of venous blood is collected and centrifuged without the anticoagulants used in many platelet-rich plasma systems. Fibrin polymerises into a matrix containing platelets, leukocytes and signalling proteins. Clinicians use it to stabilise a wound, cover graft particles and potentially support early healing.

PRF is a family of preparations

L-PRF, A-PRF, A-PRF+, injectable PRF and concentrated growth-factor protocols differ in tube material, speed, radius, time and handling. Revolutions per minute alone do not describe the force acting on cells. Results from one preparation cannot automatically be transferred to another. A clinic should document its validated protocol rather than market all concentrates as the same product.

How it is prepared

Blood is drawn immediately before treatment into approved tubes and centrifuged promptly. Layers separate according to protocol. The fibrin clot is removed from the red-cell layer and may be compressed into a membrane, cut into graft particles or used in liquid form before clotting. Timing, tube composition, centrifuge radius and temperature affect the product. Sterile handling and trained phlebotomy remain essential.

What PRF contains and does

The fibrin network acts as a temporary scaffold and reservoir for cellular signals. It may support clot stability, vascular ingrowth and soft-tissue closure. These mechanisms are biologically plausible, but laboratory growth-factor measurements do not prove a meaningful clinical outcome. Benefits must be assessed by pain, complications, tissue dimensions, histology, implant stability and long-term restoration—not by colourful descriptions of “stem cells.”

Extraction sockets

PRF plugs can fill or cover a socket. Reviews suggest improved early soft-tissue healing and reduced postoperative discomfort in some settings. A 2026 meta-analysis of randomised trials found smaller average dimensional losses and more new bone than spontaneous healing at selected time points. Study protocols and certainty varied. A large wall defect may still require a space-maintaining graft and membrane.

Wisdom-tooth surgery

PRF has been studied after lower third-molar removal for pain, swelling, dry socket and healing. Some trials report benefit, while methods and outcomes differ. It does not replace controlled surgery, clot protection, analgesia or review of infection and nerve symptoms. Patients should not pay for a guaranteed pain-free recovery based only on an adjunct.

Implant placement

PRF may coat an implant, line an osteotomy or cover the wound. Meta-analyses report improvement in early secondary stability measurements, but the relationship to shorter treatment or better long-term survival remains uncertain. Primary stability comes from implant design and native bone. PRF cannot stabilise a poorly positioned or mechanically loose implant.

Guided bone regeneration

Membranes can be layered over particulate graft or mixed into “sticky bone.” They may improve handling and soft-tissue closure. Fibrin degrades relatively quickly and usually cannot maintain a demanding space like a reinforced barrier. For major horizontal or vertical defects, PRF should generally be viewed as an adjunct unless strong case-specific evidence supports otherwise.

Sinus augmentation

PRF has been used alone or with graft beneath the sinus membrane. It may help contain particles and cover small membrane perforations in selected protocols. The elevated space, residual bone and implant stability still govern treatment. Evidence is heterogeneous, so PRF should not be presented as eliminating perforation, sinusitis or healing time.

Periodontal and soft-tissue procedures

Trials have examined PRF in intrabony periodontal defects, recession coverage and peri-implant soft-tissue augmentation. Some show improved clinical parameters, but flap design, debridement and plaque control remain fundamental. A 2026 review of implant soft-tissue augmentation reflects continued interest, not a universal guideline. Conventional connective-tissue grafting may provide more stable volume in certain indications.

Can PRF replace a bone graft?

Not reliably in every defect. PRF provides a biologically active fibrin matrix but limited structural volume. A 2025 meta-analysis found inferior bone volume to conventional grafts in large defects while reporting reduced socket resorption versus natural healing. This distinction is crucial: an intact extraction socket and a vertical ridge deficiency are different biological problems.

Who may not be suitable?

Adequate venous access and a usable blood sample are required. Severe anaemia, platelet disorders, anticoagulation, haematological disease, active systemic infection or treatments affecting blood components may change suitability. Medicines are not stopped solely to obtain PRF without medical coordination. Patients who faint with venepuncture need appropriate positioning and monitoring.

Blood draw risks

Bruising, bleeding, pain, fainting, infection and rarely nerve irritation can occur at the venepuncture site. Identity and tube labelling must prevent sample errors. Blood should be collected with single-use equipment under infection-control standards. “Natural” and “from your own blood” do not mean risk-free.

Tube and centrifuge safety

Only tubes intended and validated for clinical blood processing should be used. Tube additives, silica coatings or separator gels can alter the product and raise biocompatibility questions. The centrifuge must be maintained, balanced and operated according to protocol. Patients may ask the clinic to identify the system and preparation method.

What patients experience

The blood draw usually occurs shortly before local anaesthesia or surgery. Several tubes may be needed depending on the application. Preparation takes minutes and the product is used immediately. PRF does not numb the site; standard anaesthesia and, when appropriate, sedation are separate. Recovery is governed mainly by the underlying operation.

Possible limitations and failure

The clot may be too small, prepared too slowly or inconsistent. It can dislodge, degrade or fail to maintain space. Wound infection, graft exposure and implant failure can still occur. PRF cannot compensate for active disease, unstable fixation, tensioned closure, smoking or inaccessible prosthetic contours. Additional grafting may still be required.

Evidence quality

PRF research includes many small trials with different preparations, comparators and outcome times. Blinding is difficult and terminology is inconsistent. Meta-analysis can show average short-term benefit while clinical certainty remains limited. Claims should specify the procedure and outcome rather than saying PRF “accelerates healing” in every patient.

Costs and informed consent

Costs cover collection equipment, tubes, processing and clinical time. Consent should state whether PRF is optional, what conventional treatment would be used without it and whether it changes the surgical plan. A biologically appealing adjunct should not be bundled in a way that prevents comparison of expected absolute benefit.

Aftercare

Follow instructions for the primary procedure. Protect the clot, avoid smoking and do not manipulate a visible fibrin membrane. A pale surface can be normal fibrin rather than pus. Increasing pain, swelling, fever, drainage, bleeding or wound opening requires review. PRF does not change emergency warning signs.

PRF and postoperative pain

Some studies report lower pain scores or analgesic use after extractions, but effect size, timing and surgical difficulty vary. Pain relief may arise from better clot protection and soft-tissue healing rather than a direct anaesthetic action. PRF does not replace local anaesthesia during surgery or an appropriate analgesic plan afterward. Severe or increasing pain still requires diagnosis for dry socket, infection, retained pathology or another complication.

PRF and wound closure

Compressed membranes can cover a socket or graft and provide a flexible fibrin layer. They are not equivalent to every collagen or non-resorbable barrier because they degrade comparatively quickly and have limited space-maintaining stiffness. In a contained wound this may be adequate; in a vertical augmentation it may not be. The surgeon should state whether PRF is acting as a clot, soft-tissue dressing, graft binder or true exclusion membrane.

Why protocol reporting matters

Centrifugal force depends on rotor radius as well as speed. Tube surface, angle, delay after blood collection and compression method influence cell distribution and fibrin structure. Without these details, another clinic cannot reproduce the preparation and a published result may not apply. Responsible consent uses the specific protocol name cautiously and avoids claiming that a newer acronym is automatically more concentrated or clinically superior.

Comparing PRF with collagen products

PRF is autologous and avoids animal or donor-derived matrix, but requires venepuncture and immediate processing. Collagen plugs and membranes offer standardised dimensions and longer barrier functions depending on product. They may be used together rather than as competitors. Choice depends on containment, required durability, patient preferences, cost and operator workflow. Patients with ethical or religious concerns should receive exact material information for all non-autologous products.

Long-term outcomes

Most proposed PRF advantages concern early healing. Long-term implant survival, prosthetic maintenance and periodontal control depend on many larger factors. Even if PRF improves early stability values, loading should follow validated mechanical and biological criteria. A healthy wound at one week does not prove that a large graft has matured. Reviews and radiographs should be scheduled according to the underlying surgery rather than reduced solely because PRF was used.

Quality control in the clinic

A safe workflow confirms patient identity, tube type, expiry date and the planned number of samples before collection. Staff balance the centrifuge, record the protocol and separate the clot without contaminating it. Failed or incomplete separation can occur when collection is slow, tubes are incorrect or timing is inconsistent. The clinic should have a predefined response rather than using an uncertain product. PRF is normally prepared chairside for immediate use and should not be stored or transferred casually. These practical controls are part of treatment quality even though they are rarely visible in promotional photographs.

Choosing meaningful outcomes

Ask what difference the adjunct is expected to make in absolute terms. A statistically higher stability reading may not change the loading date; a small reduction in swelling may or may not justify venepuncture and cost. For socket preservation, dimensional change and later need for grafting are more informative than a single early radiograph. For soft tissue, thickness and long-term contour matter. Clear outcomes make consent more honest and prevent a laboratory mechanism from being sold as a guaranteed clinical transformation.

Treatment abroad

Ask which PRF protocol, tubes and centrifuge are used and what evidence supports the proposed indication. Obtain the operative record, but product-lot documentation may differ from commercial grafts because the main material is autologous. Clarify whether PRF supplements or replaces graft and who treats complications after travel.

Questions to ask

Which PRF preparation will be used?
What specific outcome is it intended to improve?
Is it optional?
Does it replace or supplement graft?
Are the tubes approved for clinical blood processing?
Do my medicines or blood conditions affect suitability?
What happens if a usable clot is not obtained?
What evidence applies to this exact procedure?

Frequently asked questions

Is PRF a stem-cell treatment?

No. It is a fibrin-based blood concentrate containing platelets, leukocytes and signalling molecules; it is not equivalent to cultured stem-cell therapy.

Is PRF the same as PRP?

No. Preparation, anticoagulants, fibrin structure and handling differ, although both are autologous platelet concentrates.

Can PRF guarantee faster implants?

No. Early stability findings do not justify a guaranteed shortened loading schedule.

Can it be used alone?

Yes in selected sockets or soft-tissue applications, but major structural defects may need graft and a durable barrier.

Sources and clinical review references

Editorial review note: Evidence reviewed 22 July 2026. Named clinician review is required before indexation.

PRF Therapy